Wire · opportunities
Decades-Old Schizophrenia Drug Wins Approval for New Formulation
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 October 2026 · Fusion42 review
The FDA approved a new, easier-to-use once-monthly subcutaneous injectable formulation of the schizophrenia drug olanzapine (Weltruza) for adults, eliminating the need for Post-Injection Delirium/Sedation Syndrome (PDSS) monitoring.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 14 sources have reported it between 9 Oct 2026 and 10 Oct 2026.
◆ ◆ The Wire takeaway
You face less regulatory friction launching long-acting schizophrenia treatments as FDA removes the need for PDSS monitoring with new olanzapine formulation. Your product can claim a simpler user experience that lowers barriers for psychiatric care providers.
◆ Coverage
14 sources · first reported 9 Oct 2026 · latest 10 Oct 2026
◆ Topics